首页> 外文期刊>Therapeutic Drug Monitoring >Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease.
【24h】

Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease.

机译:单次口服巴氯芬对小儿胃食管反流病患者的药代动力学。

获取原文
获取原文并翻译 | 示例
       

摘要

Transient relaxation of the lower esophageal sphincter (TLESR) is the predominant mechanism of gastroesophageal reflux (GER) in adults and children. Baclofen [4-amino-3-(p-chlorophenyl)-butanoic acid], a gamma-aminobutyric acid (GABA)-B receptor agonist used for the management of spasticity, has been recently shown to significantly inhibit GER in healthy adults without any relevant side effects. The objective of this study was to evaluate the pharmacokinetics of baclofen in a pediatric population with GER disease. In an open-label single-dose pharmacokinetic study, eight children with the diagnosis of GER made on clinical grounds received an oral dose of baclofen, 2.5 mg. Blood samples were drawn from an indwelling venous catheter, and urine was collected during a postdose period of 8 hours. The concentration of baclofen in these body fluids was determined using a validated high-performance liquid chromatography (HPLC) method with electrochemical detection after OPA-sulfite derivatization. Pharmacokinetic data were analyzed using the nonlinear regression program Scientist. Serum concentration-time curves could be best described using a two-compartment open model with a lag time. Mean plasma clearance (Cl) was 315.9 mL/h/kg; volume of distribution (Vd) was 2.58 L/kg; and half-life (T(1/2)beta) was 5.10 hours. No side effects were noted. As half-lives were comparable with those found in adult studies, the risk for accumulation seems not greater in children than in adults. Body composition can have a strong influence on the Vd of baclofen and, therefore, on the dose needed to obtain therapeutic plasma levels. Dosing according to clearly defined age groups with the help of therapeutic drug monitoring seems preferable. In view of the negative correlation between body weight and Vd, dosing according to body weight using adult pharmacokinetic data does not seem an effective way for using baclofen in children.
机译:食管下括约肌(TLESR)的短暂松弛是成年人和儿童胃食管反流(GER)的主要机制。 Baclofen [4-氨基-3-(对氯苯基)-丁酸],一种用于治疗痉挛的γ-氨基丁酸(GABA)-B受体激动剂,最近已显示出可以有效抑制健康成年人中的GER相关的副作用。这项研究的目的是评估巴氯芬在患有GER疾病的儿童人群中的药代动力学。在一项开放标签的单剂量药代动力学研究中,有8位临床诊断为GER的儿童接受了2.5毫克巴氯芬的口服剂量。从留置的静脉导管中抽取血样,并在给药后8小时内收集尿液。在OPA-亚硫酸盐衍生化后,采用经过验证的高效液相色谱(HPLC)方法和电化学检测,测定这些体液中巴氯芬的浓度。使用非线性回归程序科学家分析药代动力学数据。血清浓度-时间曲线可以最好地用两室开放模型来描述。平均血浆清除率(Cl)为315.9 mL / h / kg;分配体积(Vd)为2.58 L / kg;半衰期(T(1/2)beta)为5.10小时。没有发现副作用。由于半衰期可与成人研究中的半衰期相提并论,因此儿童的积累风险似乎并不比成人高。身体成分对巴氯芬的Vd有很大影响,因此对获得治疗性血浆水平所需的剂量也有很大的影响。根据明确定义的年龄组使用治疗药物监测的剂量似乎是可取的。考虑到体重与Vd之间的负相关性,使用成人药代动力学数据根据体重进行剂量给药似乎不是在儿童中使用巴氯芬的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号